Cost Optimization Success
Deveron executed $2.5 million in cost optimization, improving non-IFRS adjusted EBITDA loss by 57% year-over-year.
Enterprise Contract Wins
Closed 2 new enterprise contracts with expected sales of USD 1.5 million in 2024, adding 100,000 new samples to the U.S. lab network.
U.S. Operations Growth
U.S. operations achieved 86% year-over-year growth in fertility and 22% growth in carbon testing.
EBITDA Margin Improvement
Experienced a 36% year-over-year EBITDA margin improvement, roughly a $1.9 million enhancement.
Operating Expense Reduction
Operating expenses declined by $1.4 million year-over-year, with significant reductions in travel costs, operational payroll, and other related expenses.